Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alcohol SCHEMBL7237276 | 0.95 | IDO1 (0.51) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL695663 | 0.85 | IDO1 (0.49) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL25380681 | 0.84 | NR3C1 (0.41) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL1229784 | 0.84 | CA12 (0.52) | CA12CA1CA2CA14KDM4E | |
| SCHEMBL30996444 | 0.84 | NR3C1 (0.41) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL5273095 | 0.84 | CYP1A2 (0.41) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL30363459 | 0.84 | IDO1 (0.55) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL921944 | 0.83 | ALKBH1 (0.40) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL3593144 | 0.82 | CA12 (0.54) | IDO1HTTCA12CA1CA2 | |
| SCHEMBL9454676 | 0.80 | ABCB1 (0.56) | KDM4EABCB1L3MBTL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115577-A1 | BCL-2 Inhibitors | Eil Therapeutics, Inc. | 2025-04-10 | — | — | US | disclosed |
| WO-2025001407-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF | 浙江养生堂天然药物研究所有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4457223-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118451070-A | BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2023129553-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| CN-101889017-A | Alkoxy compounds for the treatment of diseases | ACUCELA INC | 2010-11-17 | — | — | CN | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| CN-1167111-A | Thiazolidinedione derivatives, method for preparing derivatives and pharmaceutical compositions containing same | SENGA PHARMACEUTICAL LAB INC (JP) | 1997-12-10 | — | — | CN | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | IDO1 2767/4885HTT 19/4885CA12 4643/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | IDO1 2767/4885HTT 19/4885CA12 4643/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | IDO1 2744/4885HTT 17/4885CA12 4648/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | IDO1 2767/4885HTT 19/4885CA12 4643/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | IDO1 2767/4885HTT 19/4885CA12 4643/4885 |
| US-20250115577-A1 | BCL-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | IDO1 2795/4885HTT 2679/4885CA12 2676/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | IDO1 2767/4885HTT 19/4885CA12 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.